Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22532032 | 0.79 | GAA (0.41) | MEN1MAPK1KMT2AAPLNRGAA | |
| SCHEMBL284141 | 0.74 | APLNR (0.55) | MEN1MAPK1KMT2AAPLNRGAA | |
| SCHEMBL28906797 | 0.73 | GAA (0.41) | GAAHCRTR2 | |
| SCHEMBL18756246 | 0.73 | MEN1 (0.45) | MEN1MAPK1KMT2AAPLNRGAA | |
| SCHEMBL2391753 | 0.71 | MEN1 (0.44) | MEN1MAPK1KMT2AAPLNRGAA | |
| SCHEMBL19091087 | 0.70 | GAA (0.43) | MEN1MAPK1KMT2AAPLNRGAA | |
| SCHEMBL11525177 | 0.70 | MEN1 (0.56) | MEN1MAPK1KMT2AAPLNRGAA | |
| SCHEMBL30988285 | 0.70 | ALDH1A1 (0.39) | MAPK1LMNASMN1; SMN2 | |
| SCHEMBL6823332 | 0.69 | GAA (0.39) | MEN1MAPK1KMT2AAPLNRGAA | |
| SCHEMBL18756314 | 0.69 | APLNR (0.45) | MEN1MAPK1KMT2AAPLNRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234226-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2025-02-25 | — | — | US | disclosed |
| EP-3802501-B1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPHARMA LTD (KY) | 2024-02-28 | — | — | EP | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| CN-115089586-A | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-112566902-B | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-112566902-A | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-03-25 | — | — | US | disclosed |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234226-B2 | Compounds as nuclear transport modulators and uses thereof | XPOT, XPO1, XPO5 | MEN1 1085/4885MAPK1 2107/4885KMT2A 2929/4885 |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XPOT, XPO1, XPO5 | MEN1 1085/4885MAPK1 2107/4885KMT2A 2929/4885 |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPOT, XPO1, XPO5 | MEN1 1085/4885MAPK1 2107/4885KMT2A 2929/4885 |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPOT, XPO1, XPO5 | MEN1 1085/4885MAPK1 2107/4885KMT2A 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.